A multiplexed approach to hit finding

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 3, 2009, Pages 351-357

  Slack, Mark ^a   Winkler, Dirk ^a   Krämer, Joachim ^a   Hesterkamp, Thomas ^a  

^a EVOTEC AG   (Germany)

Author keywords

False positive; Fluorescence correlation spectroscopy; High content screening; Multiplexing; Readout

Indexed keywords

BIOPHYSICS; CELL ASSAY; CELL POPULATION; CELL SCREENING; FLUORESCENCE CORRELATION SPECTROSCOPY; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE; REVIEW;

BIOLOGICAL ASSAY; DRUG EVALUATION, PRECLINICAL; HUMANS; SMALL MOLECULE LIBRARIES; SPECTROMETRY, FLUORESCENCE;

EID: 65449170117     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Fox S, Farr-Jones S, Sopchak L, Boggs A, Wang Nicely H, Khoury R, Biros M: High-throughput screening: Update on practices and success. J Biomol Screen (2006) 11(7):864-869.
2. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2007) 6(1):29-40.
3. Snowden MA, Green DVS: The impact of diversity-based, highthroughput screening on drug discovery: Chance favours the prepared mind. Curr Opin Drug Discov Dev (2008) 11(4):553-558.
4. Hallis TM, Kopp AL, Gibson J, Lebakken CS, Hancock M, VanDenHeuvel-Kramer K, Turek-EtienneT: An improved β-lactamase reporter assay: Multiplexing with cytotoxicity readout for enhanced accuracy of hit identification. J Biomol Screen (2007) 12(5):635-644.
5. Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ: Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screen (2008) 13(6): 527-537.
6. Shiau AK, Massari ME, Ozbal CC: Back to basics: Label-free technologies for small molecule screening. Comb Chem High Throughput Screen (2008) 11(3):231-237.
7. Houston JG, Banks MN, Binnie A, Brenner A, O'Connell J, Petrillo EW: Case study: Impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006. Drug Discov Today (2008) 13(1-2):44-51.
8. Sterling J, Bojanic D, Eglen RM, Heyse S, Strulovici B: Current trends in high-throughput screening. Assay Drug Dev Technol (2008) 6(4):491-504.
9. Zhu Z, Kim S, Chen T, Lin JH, Bell A, Bryson J, Dubaqule Y, Yan N, Yanchunas J, Xie D, Stoffel R et al: Correlation of highthroughput pregnane X receptor (PCR) transactivation and bindings assays. J Biomol Screen (2004) 9(6): 533-540.
10. Wu X, Glickman JF, Bowen BR, Sills MA: Comparison of assay technologies for a nuclear receptor assay screen reveals differences in the sets of identified functional antagonists. J Biomol Screen (2003) 8(4):381-392.
11. Von Ahsen O, Schmidt A, Klotz M, Parczyk K: Assay concordance between SPA and TR-FRET in high-throughput screening. J Biomol Screen (2006) 11(6):606-616.
12. Klumpp M, Boettcher A, Becker D, Meder G, Blank J, Leder L, Forstner M, Ottl J, Mayr LM: Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. J Biomol Screen (2006) 11(6):617-633.
13. Schröter T, Minond D, Weiser A, Dao C, Habel J, Spicer T, Chase P, Balllargeon P, Scampavla L, Schürer S, Chung C et al: Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II). J Biomol Screen (2008) 13(1): 17-28.
14. Kashem MA, Nelson RM, Yingling JD, Pullen SS, Prokopowlcz AS, Wildeson Jones J, Wolak JP, Rogers GR, Morelock MM, Snow RJ, Homon CA et al: Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors. J Biomol Screen (2007) 12(1):70-83.
15. Quercia AK, LaMarr WA, Myung J, Ozbal CC, Landro JA, Lumb KJ: High-throughput screening by mass spectrometry: Comparison with the scintillation proximity assay with a focused-file screen of AKT1/PKBa. J Biomol Screen (2007) 12(4):473-480.
16. Heilker R, Zemanova L, Valler MJ, Nienhaus GU: Confocal fluorescence microscopy for high-throughput screening of G-protein coupled receptors. Curr Med Chem (2005) 12 (22):2551-2559.
17. Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill WAG, Popov M, Jacoby E et al: Which aspects of HTS are empirically correlated with downstream success? Curr Opin Drug Discov Dev (2008) 11(3):327-337.
18. Woelcke J, Hunt N, Jungmann J, Ullmann D: Early identification of false positives in high-throughput screening for activators of p53-DNA interaction. J Biomol Screen (2006) 11(4):341-350.
19. Vazquez MJ, Ashman S, Ramon F, Calvo D, Bardera A, Martin JJ, Rüdiger M, Tew D, Dominguez JM: Utilization of substrate-induced quenching for screening targets promoting NADH and NADPH consumption. J Biomol Screen (2006) 11(1):75-81.
20. Hesterkamp T, Barker J, Davenport A, Whittaker M: Fragment based drug discovery using fluorescence correlation spectroscopy techniques: Challenges and solutions. Curr Top Med Chem (2007) 7(16):1582-1591.
21. Kostka M, Hoegen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P et al: Single particle characterization of iron-induced pore forming α-synuciein oligomers. J Biol Chem (2008) 283(16):10992-11003.
22. Kim SA, Heinze KG, Schwille P: Fluorescence correlation spectroscopy in living cells. Nat Methods (2007) 4(11):963-973.
23. Korn K, Krausz E: Cell-based high-content screening of small molecule libraries. Curr Opin Chem Biol (2007) 11(5):503-510.
24. Garippa RJ, Hoffman AF, Gradl G, Kirsch A: High-throughput confocal microscopy for β-arrestin - Green fluorescent protein translocation G-protein coupled receptor assays using the Evotec Opera. Methods Enzymol (2006) 414:99-120.
25. Denner P, Schmalowsky J, Prechtl S: High-content analysis in preclinical drug discovery. Comb Chem High Throughput Screen (2008) 11(3):216-230.
26. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, Feng Y: Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol (2008) 4(1):59-68.
27. Adams CL, Kutsyy V, Coleman DA, Cong G, Crompton AM, Ellas KA, Oestrelcher DR, Trautman JK, Vaisberg E: Compound classification using image-based cellular phenotypes. Methods Enzymol (2006) 414:440-468.
28. Nickischer D, Laethem C, Trask OJ, Williams RG, Kandasamy R, Johnston PA, Johnston PA: Development and implementation of three mitogen-actlvated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun and ERK activation. Methods Enzymol (2006) 414:389-418.
29. Ross S, Chen T, Yu V, Tudor Y, Zhang D, Liu L, Tamayo N, Dominguez C, Powers D: High-content screening analysis of the p38 pathway: Profiling of structurally related p38α kinase inhibitors using cell-based assays. Assay Drug Dev Technol (2006) 4(4): 397-409.
30. Low J, Stancato L, Lee J, Sutherland JJ: Prioritizing hits from phenotypic high-content screens. Curr Opin Drug Discov Dev (2008) 11(3):338-345.
31. Haasen D, Merk S, Seither P, Martyres D, Hobble S, Heilker R: Pharmacological profiling of chemokine receptor-directed compounds using high-content screening. J Biomol Screen (2008) 13(1):40-53.
32. Ross DA, Reiser LV, Xue J, Alves K, Vaidya S, Kreamer A, Mull R, Hudak E, Hare T, Detmers PA, Lingham M et al: Multiplexed assays by high-content imaging for assessment of GPCR activity. J Biomol Screen (2008) 13(6):449-455.
33. Henriksen U, Fog J, Loechel F, Praestegaard M: Profiling of multiple signal pathway activities by multiplexing antibody and GFP-based translocation assays. Comb Chem High Throughput Screen (2008) 11(7):537-544.
34. Daniels DW: High-content screening rapidly evolving. Genet Eng Biotechnol News (2009) 29(1). genengnews.com/articles/chitem. aspx?aid=2723
35. 2+] flux kinetics in high-throughput screening. J Biomol Screen (2006) 11(5):511-518.
36. Crisman TJ, Parker CN, Jenkins JL, Scheiber J, Thoma M, Kang ZB, Kim R, Bender A, Nettles JH, Davies JW, Glick M: Understanding false positives in reporter gene assays: In silico chemogenomics approaches to prioritize cell-based HTS data. J Chem Inf Mod (2007)47(4):1319-1327.
37. Hanson J: Multiplexing Fluo-NW and a GeneBlazer transcriptional assay for high-throughput screening of G-proteln-coupled receptors. J Biomol Screen (2006) 11(6):644-651.
38. Tran E, Fang Y: Duplexed label-free G protein-coupled receptor assays for high-throughput screening. J Biomol Screen (2008) 13(10):1-11.
39. 1coupled GPCRs. J Biomol Screen 12(3):312-319.
40. Krutzik PO, Crane JM, Clutter MR, Nolan GP: High-content single-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol (2008) 4(2):132-141.
41. Wylie PG: Multiple cell lines using quantum dots. Methods Mol Biol (2007) 374:113-123.
42. Yoo J, Kambara T, Gonda K, Higuchi H: Intracellular imaging of targeted proteins labeled with quantum dots. Exp Cell Res (2008) 314(19):3563-3569.
43. Babaoglu K, Simeonov A, Irwin JJ, Nelson ME, Feng B, Thomas CJ, Cancian L, Cost! MP, Maltby DA, Jadhav A, Inglese J et al: Comprehensive mechanistic analysis of hits from highthroughput and docking screens against β-lactamase. J Med Chem (2008) 51(8):2502-2511.
44. Rich RL, Myzska DG: Higher-throughput, label-free technology in drug discovery. Anal Biochem (2008) 361(1): 1-6.
45. Lee PH, Gao A, van Staden C, Ly J, Salon J, Xu A, Fang Y, Verkleeren R: Evaluation of dynamic mass distribution technology for pharmacological studies of recombinant and endogenously expressed G protein-coupled receptors. Assay Drug Dev Technol (2008) 6(1):83-94.
46. Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, Jahnke W, James TL, Homans SW, Kessler H, Luchinat C, Meyer B et al: Perspectives on NMR in drug discovery: A technique comes of age. Nat Rev Drug Discov (2008) 7(9): 738-745.
47. Hubbard RE, Davis B, Chen I, Drysdale M: The SeeDs approach: Integrating fragments into drug discovery. Curr Top Med Chem
48. Roddy TP, Horvath CR, Stout SJ, Kenney KL, Ho PI, Zhang JH, Vickers C, Kaushik V, Hubbard B, Wang YK: Mass spectrometric techniques for label-free high-throughput screening in drug discovery. Anal Chem (2007) 79(21):8207-8213.
49. Tolonen A, Petsalo A, Turpeinen M, Uusltalo J, Pelkonen O: In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/ MSMS run: Analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom (2007) 42(7):960-966.
50. 50 assay using a rapid resolution LC-MS/MS end-point. J Pharm Biomed Anal (2008) 48(1):92-99.
51. Zientek M, Miller H, Smith D, Dunklee MB, Heinle L, Thurston A, Lee C, Hyland R, Fahml O, Burdette D: Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods (2008) 58(3):206-214.
52. Wu WW, Wang G, Liang XJ, Park JK, Shen RF: Covalent modification of stathmin by CCNU determined by FTMS analysis of modified proteins and tryptic peptides. Biochem Biophys Res Comm (2008) 367(1):7-13.